Literature DB >> 3442670

Genetic polymorphism of human cytochrome P-450 (S)-mephenytoin 4-hydroxylase. Studies with human autoantibodies suggest a functionally altered cytochrome P-450 isozyme as cause of the genetic deficiency.

U T Meier1, U A Meyer.   

Abstract

The metabolism of the anticonvulsant mephenytoin is subject to a genetic polymorphism. In 2-5% of Caucasians and 18-23% of Japanese subjects a specific cytochrome P-450 isozyme, P-450 meph, is functionally deficient or missing. We have accumulated evidence that autoimmune antibodies observed in sera of patients with tienilic acid induced hepatitis (anti-liver kidney microsome 2 or anti-LKM2 antibodies) specifically recognize the cytochrome P-450 involved in the mephenytoin hydroxylation polymorphism. This is demonstrated by immunoinhibition and immunoprecipitation of microsomal (S)-mephenytoin 4-hydroxylation activity and by the recognition by anti-LKM2 antibodies of a single protein band on immunoblots of human liver microsomes after sodium dodecyl sulfate-polyacrylamide gel electrophoresis or isoelectric focusing. The cytochrome P-450 recognized by anti-LKM2 antibodies was immunopurified from microsomes derived from livers of extensive (EM) or poor metabolizers (PM) of (S)-mephenytoin. Comparison of the EM-type cytochrome P-450 to that isolated from PM livers revealed no difference in regard to immuno-cross-reactivity, molecular weight, isoelectric point, relative content in microsomes, two-dimensional tryptic peptide maps, one-dimensional peptide maps with three proteases, amino acid composition, and amino-terminal protein sequence. Finally, the same protein was precipitated from microsomes prepared from the liver biopsy of a subject phenotyped in vivo as a poor metabolizer of mephenytoin. These data strongly suggest that the mephenytoin hydroxylation deficiency is caused by a minor structural change leading to a functionally altered cytochrome P-450 isozyme.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3442670     DOI: 10.1021/bi00399a065

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  10 in total

1.  Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics.

Authors:  L M Forrester; C J Henderson; M J Glancey; D J Back; B K Park; S E Ball; N R Kitteringham; A W McLaren; J S Miles; P Skett
Journal:  Biochem J       Date:  1992-01-15       Impact factor: 3.857

Review 2.  Cytochrome P450 enzymes as human autoantigens.

Authors:  M P Manns
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

Review 3.  Molecular basis of polymorphic drug metabolism.

Authors:  A K Daly
Journal:  J Mol Med (Berl)       Date:  1995-11       Impact factor: 4.599

4.  Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1.

Authors:  M P Manns; E F Johnson; K J Griffin; E M Tan; K F Sullivan
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

5.  In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme.

Authors:  N A Helsby; S A Ward; R E Howells; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

6.  Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans.

Authors:  D Busse; J Cosme; P Beaune; H K Kroemer; M Eichelbaum
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-12       Impact factor: 3.000

7.  Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450IA2. A specific marker of dihydralazine-induced hepatitis.

Authors:  M Bourdi; D Larrey; J Nataf; J Bernuau; D Pessayre; M Iwasaki; F P Guengerich; P H Beaune
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

8.  Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II.

Authors:  U M Zanger; H P Hauri; J Loeper; J C Homberg; U A Meyer
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

Review 9.  Omeprazole drug interaction studies.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

10.  Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark.

Authors:  A Drøhse; L Bathum; K Brøsen; L F Gram
Journal:  Br J Clin Pharmacol       Date:  1989-05       Impact factor: 4.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.